AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$GLSI

Greenwich LifeSciences, Inc.

Price · $GLSIvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $GLSI in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $GLSI in the last 30 days.

Top stories · $GLSIMore →
APR 30·Stock TitanMed

Europe trial enrollment jump leaves Greenwich finalizing 10-K figures

Greenwich LifeSciences (GLSI) announced its Form 10-K for fiscal 2025 is still under audit, with auditors expecting completion by the end of May, coinciding with the Q1 2026 Form 10-Q filing. The delay is primarily due to final adjustments needed for accounts payable related to the large global Phase III clinical trial, FLAMINGO-01, especially an unexpectedly high enrollment increase in Europe during 2024 and 2025. The company reiterated an unaudited cash balance of approximately $10.5 million as of March 31, 2026.

APR 30·GlobeNewswire

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences (Nasdaq: GLSI) provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025, stating that auditors expect to complete their review by the end of May. The delay is attributed to adjustments related to accounts payable for its Phase III clinical trial, FLAMINGO-01, and increased patient enrollment in Europe. The company also reported an unaudited cash balance of approximately $10.5 million as of March 31, 2026, and shared preliminary positive recurrence rate data from the FLAMINGO-01 trial.

DEC 19·TipRanks

Greenwich LifeSciences Stockholders Reelect Board and Auditor

Greenwich LifeSciences (GLSI) stockholders re-elected all five director nominees and ratified MaloneBailey LLP as the independent auditor for the fiscal year ending December 31, 2025, during their Annual Meeting on December 18, 2025. This decision ensures continuity in both the board's composition and the company's audit oversight. The company, a biopharmaceutical firm focused on breast cancer immunotherapies, currently has an analyst rating of "Buy" with a $45.00 price target.

News on $GLSI

All news →